Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study

Giuseppe Gregori, Ornella Righi, Paolo Risso, Goffreda Boiardi, Giovanni Demuru, Anna Ferzetti, Antonio Galli, Marco Ghisoni, Sonia Lenzini, Claudio Marenghi, Caterina Mura, Roberto Sacchetti, Lucia Suzzani, Giuseppe Gregori, Ornella Righi, Paolo Risso, Goffreda Boiardi, Giovanni Demuru, Anna Ferzetti, Antonio Galli, Marco Ghisoni, Sonia Lenzini, Claudio Marenghi, Caterina Mura, Roberto Sacchetti, Lucia Suzzani

Abstract

Recurrent pharyngo-tonsillar infections caused by group A beta-hemolytic streptococci (GABHS) occur frequently in young children, and the treatment of these infections contributes substantially to the total current requirement for antibiotic prescribing. Our study goal was to assess through a retrospective observational analysis whether the administration of the oral probiotic, Streptococcus salivarius K12 (SsK12), could reduce the occurrence of GABHS pharyngo-tonsillar infections in children who had a recent history of recurrent episodes of these infections. Twelve primary care pediatricians identified, through their databases, a total of 130 children who had experienced recurrent GABHS pharyngo-tonsillar infections over a period of at least 6-12 months prior to their inclusion in the study. Of these children, 76 then undertook a 90-day program requiring once-a-day dosing with a commercially available (Bactoblis) lozenge containing SsK12. No probiotic supplement was given to the remaining 54 (control) children. Each subject was monitored for the occurrence of GABHS pharyngo-tonsillitis and also for acute otitis media, bronchitis, sinusitis, and bronchopneumonia for at least 12 months following their entry to the study. Even 9 months after the use of SsK12 had been stopped, the probability of new GABHS infections was significantly lower (P>0.001) when compared to the period before dosing commenced. When compared to the untreated children, those taking SsK12 appear to have had significantly fewer GABHS infections both during the 90-day period of prophylaxis and during the following 9 months (P<0.001). These observations are supportive of the use of probiotic SsK12 for the control of recurrent GABHS pharyngo-tonsillar infections in children, and as an associated benefit, the use of this probiotic could lead to reduced antibiotic consumption. Follow-up controlled prospective studies should now be initiated in order to further establish the efficacy of this newly emerging prophylactic strategy.

Keywords: Streptococcus salivarius K12; group A beta-hemolytic streptococcus; recurrent pharyngo-tonsillar infections.

References

    1. Van Driel ML, De Sutter AIM, Keber N, Habraken H, Christiaens T. Different antibiotic treatments for group A streptococcal pharyngitis. Cochrane Database Syst Rev. 2013;(4):CD004406.
    1. Spinks A, Glasziou PP, DelMar CB. Antibiotics for sore throat. Cochrane Database Syst Rev. 2013;(11):CD000023.
    1. Tagg JR. Streptococci as effector organism for probiotic and replacement therapy. In: Versalovic J, Wilson M, editors. Therapeutic Microbiology: Probiotics and Related Strategies. Washington DC: ASM Press; 2008. pp. 61–81.
    1. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting ‘germ warfare’ to infection prevention. Trends Biotechnol. 2003;21(5):217–223.
    1. Di Pierro F, Donato G, Fornia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–997.
    1. McIsaac WJ, Kellner JD, Aufricht P, Vanjaka A, Low DE. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA. 2004;291(13):1587–1595.
    1. E-R Agenzia sanitaria e sociale regionale. Dossier n.153/2007 – Farin-gotonsillite in età pediatrica. Linea Guida regionale [update February 15, 2013] [Accessed March 24, 2015]. Available from: .
    1. Di Mario S, Gagliotti C, Moro ML. Nuovelinee Guidafaringotonsillite – Regione Emilia – Romagna. Jun, 2015. Available from: .
    1. National Institute for Health and Clinical Excellence. Centre for Clinical Practice . Respiratory tract infections – antibiotic prescribing Prescribing of antibiotics for selflimiting respiratory tract infections in adults and children in primary care (Clinical guideline; no 69) London, UK: NICE; 2008.
    1. Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004;119(Suppl):13–16.
    1. Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg JR. Preliminary investigations of the colonization of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis. 2008;27(12):1261–1263.
    1. Horz HP, Meinelt A, Houben B, Conrads G. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol. 2007;22(2):126–130.
    1. Burton JP, Wescombe PA, Moore CJ, Chilcott CN, Tagg JR. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol. 2006;72(4):3050–3053.
    1. Burton J, Chilcott C, Wescombe P, Tagg J. Extended safety data for the oral cavity probiotic Streptococcus salivarius K12. Probiot Antimicrob Proteins. 2010;2:135–144.
    1. Ruvuna F. Unequal center sizes, sample size, and power in multicenter clinical trials. Drug Inf J. 2004;38(4):387–394.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj